Surmodics, Inc. SRDX delivered earnings per share (EPS) of 7 cents in the second quarter of fiscal 2024 against the year-ago quarter’s loss of 40 cents per share. The metric beat the Zacks Consensus Estimate of a loss of 36 cents per share by 119.4%. GAAP EPS for the quarter was 2 cents, narrower than the year-earlier loss of 55 cents per share. Revenues in Detail Surmodics registered revenues of $31.9 million in the fiscal second quarter, up 18% year over year. The figure surpassed the Zacks Consensus Estimate by 11%. The top line was boosted by solid year-over-year product sales growth from the Medical Device business. Excluding SurVeil drug-coated balloon (DCB) license fee revenues, total revenues increased 19% year over year to $30.9 million. Segmental Analysis Surmodics operates via two reportable segments — Medical Device and IVD. In the reported quarter, sales in the Medical Device segment summed $24.8 million, up 26% from the year-ago quarter. Excluding SurVeil DCB license fee revenues, Medical Device revenues increased 29% to $23.7 million year over year. This figure compares to our Medical Device fiscal second-quarter revenue projection of $22.5 million. Medical Device revenue growth was primarily driven by product sales of $11.1 million, up 40% year over year. Product sales growth was driven primarily by fulfillment of the initial stocking order for the SurVeil DCB from Abbott (Surmodics’ exclusive distribution partner for the product) and continued sales growth from the Pounce thrombectomy device platform. In the quarter under review, IVD sales declined 5% to $11 million, primarily driven by lower sales of colorimetric substrate products. This figure compares to our IVD fiscal second-quarter revenue projection of $6.3 million. The company also derives revenues from three primary sources — Product sales, Royalties and license fees and Research, development and other fees. In the quarter under review, Product sales were $18.1 million, up 17.9% from the prior-year quarter. This figure compares to our fiscal second-quarter revenue projection of $17.7 million. Royalties and license fees revenues totaled $11.4 million, up 21% from the prior-year quarter. This figure compares to our fiscal second-quarter revenue projection of $9.5 million. Research, development and other revenues were $2.4 million, up 1.2% year over year. This figure compares to our fiscal second-quarter revenue projection of $1.6 million. Margin Trend In the quarter under review, Surmodics’ gross profit increased 15.8% to $24.9 million. However, the gross margin contracted 120 basis points to 77.7%. We had projected 76.2% of gross margin for the fiscal second quarter. Selling, general & administrative expenses increased 0.9% to $13.1 million. Research and development expenses increased 1% year over year to $8.8 million. Operating expenses, excluding product costs, decreased 14% to $24.2 year over year. Adjusted operating profit totaled $1.5 million against the prior-year quarter’s adjusted operating loss of $4.4 million. Financial Position Surmodics exited second-quarter fiscal 2024 with cash and cash equivalents of $33 million compared with $23.4 million at the end of the fiscal first quarter of 2024. Total long-term debt at the end of second-quarter fiscal 2024 was $29.5 million. Net cash used in operating activities at the end of second-quarter fiscal 2024 was $1.4 million compared with $16.6 million a year ago. Fiscal 2024 Guidance Surmodics has revised its financial outlook for fiscal 2024. The company now projects fiscal 2024 revenues in the range of $122 million-$124 million, representing a decrease of 8-6% over the comparable prior-year period. This is raised and tightened from the earlier projection of $117 million-$121 million. The Zacks Consensus Estimate currently stands at $120.6 million. Excluding SurVeil DCB license fee revenues, Surmodics now expects fiscal 2024 total revenues between $118 million and $120 million, representing an increase of 15-17% compared with fiscal 2023. This is raised and tightened from the prior outlook of revenues between $113 million and $117 million, representing an increase of 10-14% compared to fiscal 2023. Adjusted loss per share for fiscal 2024 is now expected to be in the range of 47-67 cents. This compares with the earlier provided projections of a loss per share of 87 cents to $1.17. The Zacks Consensus Estimate currently stands at a loss of 90 cents per share. Our Take Surmodics exited the second quarter of fiscal 2024 with better-than-expected results. The solid uptick in the overall top line and bottom line was impressive. The company registered robust revenues from its medical device and its primary sources, which was encouraging. Per the fiscal second-quarter earnings release, Surmodics announced the completion of limited market evaluation (LME) and commercial launch of two new mechanical thrombectomy systems for the peripheral venous and arterial vasculatures, the Pounce Venous Thrombectomy System and the Pounce LP (Low Profile) Thrombectomy System. In January, Surmodics announced the successful early clinical use and LME of the Pounce LP Thrombectomy System, which is designed for the removal of acute-to-chronic thrombi and emboli in peripheral arteries ranging from 2 mm to 4 mm, such as those found below the knee. However, the gross margin contraction does not bode well for Surmodics. Continued adverse impacts due to supply-chain challenges also raise our apprehension. Surmodics, Inc. Price, Consensus and EPS Surprise Surmodics, Inc. Price, Consensus and EPS Surprise Surmodics, Inc. price-consensus-eps-surprise-chart | Surmodics, Inc. Quote Zacks Rank and Key Picks Surmodics currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space that have announced quarterly results are Align Technology, Inc. ALGN, Ecolab ECL and Boston Scientific Corporation BSX. Align Technology, carrying a Zacks Rank of 2 (Buy), reported first-quarter 2024 adjusted EPS of $2.14, beating the Zacks Consensus Estimate by 8.1%. Revenues of $997.4 million outpaced the consensus mark by 2.6%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Align Technology has a long-term estimated growth rate of 6.9%. ALGN’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 5.9%. Ecolab, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 13.3%. ECL’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 1.7%. Ecolab’s shares have rallied 33.8% against the industry’s 9.3% decline in the past year. Boston Scientific reported first-quarter 2024 adjusted EPS of 56 cents, beating the Zacks Consensus Estimate by 9.8%. Revenues of $3.86 billion surpassed the Zacks Consensus Estimate by 4.9%. It currently carries a Zacks Rank #2. Boston Scientific has a long-term estimated growth rate of 12.5%. BSX’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 7.5%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX):Free Stock Analysis Report Ecolab Inc. (ECL):Free Stock Analysis Report Align Technology, Inc. (ALGN):Free Stock Analysis Report Surmodics, Inc. (SRDX):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
Surmodics (SRDX) Q2 Earnings Top Estimates, '24 View Up
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...